Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

47.24 -0.48 (-1.00%)

Streaming Delayed Price Updated: 3:50 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

The Best Healthcare Stock to Hold in Uncertain Times ↗

Today 6:50 EST

Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning.

Via The Motley Fool

Topics Economy World Trade

AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps

November 10, 2025

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...

Via TokenRing AI

Topics Artificial Intelligence

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗

November 10, 2025

AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs.

Via Benzinga

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

GSK Buys Global Rights To Preclinical Cancer Therapy For $357M ↗

October 27, 2025

Via Stocktwits

Looking Into GSK PLC's Recent Short Interest ↗

November 07, 2025

Via Benzinga

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

The Fading Luster: Is the "Gold Rush Over" While Stocks Remain "Overheated"?

November 05, 2025

The financial markets are currently grappling with a potent and increasingly vocal narrative: the "gold rush is over" for commodities, particularly gold, while the stock market, especially in certain...

Via MarketMinute

Topics Artificial Intelligence Cannabis ETFs

AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency

October 31, 2025

The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing...

Via TokenRing AI

Topics Artificial Intelligence Economy Fraud

2 High-Yield Stocks With Fresh Catalysts ↗

October 29, 2025

Income investors can capture yields above 5% from companies executing business transformations.

Via The Motley Fool

Topics Lawsuit

Navigating the Turbulence: Understanding Market Volatility Amidst Record Highs

October 29, 2025

As late 2025 unfolds, the global stock market presents a fascinating paradox: major U.S. indices, including the S&P 500, Dow Jones Industrial Average (NYSE: ^DJI), and Nasdaq Composite (NASDAQ: ^IXIC),...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Bonds

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 ↗

October 29, 2025

GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2025 outlook.

Via Benzinga

GSK Jumps After Hiked 2025 Guidance Widely Outperforms Expectations ↗

October 29, 2025

GSK stock rose early Wednesday on strong 2025 guidance on the back of its third-quarter sales and earnings beat.

Via Investor's Business Daily

Dow Jones Soars to New Record High Amidst Wave of Optimism, Signaling Robust Market Confidence

October 27, 2025

The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep ↗

October 24, 2025

FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.

Via Benzinga

GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short ↗

October 24, 2025

The company won approval for its drug, Blenrep. But it wasn't enough.

Via Investor's Business Daily

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce ↗

October 22, 2025

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.

Via Benzinga

Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes

October 17, 2025

The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements...

Via TokenRing AI

Topics Artificial Intelligence Economy

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment ↗

October 17, 2025

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication.

Via Benzinga

AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals

October 14, 2025

A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Economy Intellectual Property Retirement

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields ↗

October 01, 2025

Via Benzinga

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Via MarketMinute

Topics Economy Government World Trade

AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗

September 30, 2025

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas.

Via Benzinga

GSK’s First Female CEO Steps Down After Nearly A Decade — Retail Hopes New Leadership Can Revive Lagging Stock ↗

September 30, 2025

Emma Walmsley’s departure comes as GSK works to strengthen its drug pipeline and offset the upcoming loss of patent protection on its top-selling HIV drug, dolutegravir.

Via Stocktwits

Topics Intellectual Property

AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth

September 29, 2025

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York...

Via MarketMinute

Topics Economy

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 ↗

September 29, 2025

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma...

Via Benzinga

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Starting at $3.75/week.

Subscribe Today